Sansure Biotech Inc.

Symbol: 688289.SS

SHH

20.62

CNY

Market price today

  • 31.0215

    P/E Ratio

  • 0.0048

    PEG Ratio

  • 11.83B

    MRK Cap

  • 0.03%

    DIV Yield

Sansure Biotech Inc. (688289-SS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.73%

Operating Profit Margin

0.33%

Net Profit Margin

0.32%

Return on Assets

0.04%

Return on Equity

0.05%

Return on Capital Employed

0.05%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO:Mr. Lizhong Dai
Full-time employees:2567
City:Changsha
Address:No. 680, Lusong Road
IPO:2020-08-28
CIK:

Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.

General Outlook

When we look at how much money they make before expenses, they keep 0.729% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.334%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.321%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.044% return, is a testament to Sansure Biotech Inc.'s adeptness in optimizing resource deployment. Sansure Biotech Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.053%. Furthermore, the proficiency of Sansure Biotech Inc. in capital utilization is underscored by a remarkable 0.050% return on capital employed.

Stock Prices

Sansure Biotech Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $19.59, while its low point bottomed out at $19.25. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Sansure Biotech Inc.'s stock market.

Liquidity Ratios

Analyzing 688289.SS liquidity ratios reveals its financial health of the firm. The current ratio of 847.68% gauges short-term asset coverage for liabilities. The quick ratio (783.08%) assesses immediate liquidity, while the cash ratio (600.79%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio847.68%
Quick Ratio783.08%
Cash Ratio600.79%

Profitability Ratios

688289.SS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 37.39% underscores its earnings before tax deductions. The effective tax rate stands at 15.81%, revealing its tax efficiency. The net income per EBT, 85.92%, and the EBT per EBIT, 111.91%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 33.41%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin37.39%
Effective Tax Rate15.81%
Net Income per EBT85.92%
EBT per EBIT111.91%
EBIT per Revenue33.41%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 8.48, it details the span from stock purchase to revenue. The 8 days it takes to settle debts showcases its creditor relations. Meanwhile, a 6 cash conversion cycle and 171.86% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding783
Days of Inventory Outstanding433
Operating Cycle645.58
Days of Payables Outstanding411
Cash Conversion Cycle235
Receivables Turnover1.72
Payables Turnover0.89
Inventory Turnover0.84
Fixed Asset Turnover1.15
Asset Turnover0.14

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.09, and free cash flow per share, -0.50, depict cash generation on a per-share basis. The cash per share value, 8.63, showcases liquidity position. A payout ratio of 1.05 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.04, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.09
Free Cash Flow per Share-0.50
Cash per Share8.63
Payout Ratio1.05
Operating Cash Flow Sales Ratio0.04
Free Cash Flow to Operating Cash Flow Ratio-5.60
Cash Flow Coverage Ratio0.11
Short Term Coverage Ratio0.78
Capital Expenditure Coverage Ratio0.15
Dividend Paid and Capex Coverage Ratio0.07
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 5.20%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing. The long-term debt to capitalization, 5.07%, and total debt to capitalization, 5.86%, ratios shed light on its capital structure. An interest coverage of 53.30 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio5.20%
Debt Equity Ratio0.06
Long Term Debt to Capitalization5.07%
Total Debt to Capitalization5.86%
Interest Coverage53.30
Cash Flow to Debt Ratio0.11
Company Equity Multiplier1.20

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.75, provides a glimpse into top-line earnings distributed across each share. Net income per share, 0.64, reflects the portion of profit attributed to each share. The book value per share, 12.59, represents the net asset value distributed per share, while the tangible book value per share, 12.45, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share1.75
Net Income Per Share0.64
Book Value Per Share12.59
Tangible Book Value Per Share12.45
Shareholders Equity Per Share12.59
Interest Debt Per Share0.17
Capex Per Share-0.68

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -84.40%, indicates top-line expansion, while the gross profit growth, -73.48%, reveals profitability trends. EBIT growth, -80.89%, and operating income growth, -80.89%, offer insights into operational profitability progression. The net income growth, -81.40%, showcases bottom-line expansion, and the EPS growth, -81.19%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-84.40%
Gross Profit Growth-73.48%
EBIT Growth-80.89%
Operating Income Growth-80.89%
Net Income Growth-81.40%
EPS Growth-81.19%
EPS Diluted Growth-81.19%
Weighted Average Shares Growth-1.19%
Weighted Average Shares Diluted Growth-1.19%
Dividends per Share Growth-100.00%
Operating Cash Flow Growth-100.00%
Free Cash Flow Growth-100.00%
10-Year Revenue Growth per Share181.27%
5-Year Revenue Growth per Share108.18%
3-Year Revenue Growth per Share-78.12%
10-Year Operating CF Growth per Share100.00%
5-Year Operating CF Growth per Share-100.00%
3-Year Operating CF Growth per Share-100.00%
10-Year Net Income Growth per Share2222.39%
5-Year Net Income Growth per Share3243.71%
3-Year Net Income Growth per Share-85.75%
10-Year Shareholders Equity Growth per Share1130.38%
5-Year Shareholders Equity Growth per Share1076.67%
3-Year Shareholders Equity Growth per Share62.08%
10-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Receivables Growth-100.00%
Inventory Growth-100.00%
Asset Growth-100.00%
Book Value per Share Growth0.24%
Debt Growth-100.00%
R&D Expense Growth-100.00%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 6,859,231,469.72, captures the company's total value, considering both debt and equity. Income quality, 0.31, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.07, gauges operational efficiency, while the research and development to revenue, 16.67%, highlights investment in innovation. The ratio of intangibles to total assets, 3.97%, indicates the value of non-physical assets, and capex to operating cash flow, -346.88%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value6,859,231,469.72
Income Quality0.31
Sales General and Administrative to Revenue0.07
Research and Development to Revenue16.67%
Intangibles to Total Assets3.97%
Capex to Operating Cash Flow-346.88%
Capex to Revenue-39.04%
Capex to Depreciation-286.15%
Stock-Based Compensation to Revenue0.62%
Graham Number13.42
Return on Tangible Assets4.48%
Graham Net Net7.90
Working Capital5,030,441,048
Tangible Asset Value7,121,766,083
Net Current Asset Value4,952,783,057
Average Receivables1,102,746,989.5
Average Payables630,032,279.5
Average Inventory365,972,942
Days Sales Outstanding267
Days Payables Outstanding448
Days of Inventory On Hand360
ROIC-0.21%
ROE0.05%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.63, and the price to book ratio, 1.63, reflect the market's valuation relative to the company's book value. The price to sales ratio, 9.97, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -41.99, and price to operating cash flows, 235.03, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.63
Price to Book Ratio1.63
Price to Sales Ratio9.97
Price Cash Flow Ratio235.03
Enterprise Value Multiple41.39
Price Fair Value1.63
Price to Operating Cash Flow Ratio235.03
Price to Free Cash Flows Ratio-41.99
Price to Tangible Book Ratio1.53
Enterprise Value to Sales6.84
Enterprise Value Over EBITDA57.76
EV to Operating Cash Flow60.80
Earnings Yield3.31%
Free Cash Flow Yield-2.53%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sansure Biotech Inc. (688289.SS) on the SHH in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 31.022 in 2024.

What is the ticker symbol of Sansure Biotech Inc. stock?

The ticker symbol of Sansure Biotech Inc. stock is 688289.SS.

What is company IPO date?

IPO date of Sansure Biotech Inc. is 2020-08-28.

What is company current share price?

Current share price is 20.620 CNY.

What is stock market cap today?

The market cap of stock today is 11826032094.000.

What is PEG ratio in 2024?

The current 0.005 is 0.005 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2567.